Matrix Capital Management Company, LP 13D and 13G filings for Adaptimmune Therapeutics plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-08 10:30 am Sale |
2024-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 0 0.000% |
-135,000,000 (Position Closed) |
Filing |
| 2024-12-05 5:17 pm Sale |
2024-11-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 135,000,000 8.800% |
-91,089,090 (-40.29%) |
Filing |
| 2024-11-13 09:04 am Sale |
2024-09-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 226,089,090 14.730% |
-7,756,020 (-3.32%) |
Filing |
| 2023-07-10 4:15 pm Unchanged |
2023-06-30 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 233,845,110 17.290% |
0 (Unchanged) |
Filing |
| 2021-02-16 10:03 am Purchase |
2020-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Matrix Capital Management Company, LP | 233,845,110 25.180% |
65,845,110 (+39.19%) |
Filing |